Form 4: Vigil Neuroscience Director Booth Receives Stock Option Award in Lieu of Cash Compensation

Director Bruce Booth of Vigil Neuroscience, Inc. was granted a stock option award for 48,393 shares in lieu of cash compensation, vesting quarterly starting March 31, 2025.

Summary

• On March 3, 2025, Bruce Booth, a director of Vigil Neuroscience, Inc., received a stock option award for 48,393 shares of common stock.
• The exercise price of the stock options is $2.19 per share.
• The options were granted in lieu of cash compensation under the company's Non-Employee Director Compensation Policy.
• The stock options vest in four equal quarterly installments, beginning on March 31, 2025.
• The options expire on March 3, 2035.
• Booth is a member of Atlas Venture Associates XII, LLC and will transfer any economic benefit from the sale of these shares to Atlas Venture Life Science Advisors, LLC, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation matter, which is generally neutral to positive as it aligns director interests with shareholders. The sentiment is slightly positive as it indicates ongoing commitment from a director.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Future Outlook

The director's compensation structure is set for the coming years, with vesting occurring quarterly until the options are fully vested.

Industry Context

Stock option awards are a common form of compensation for directors, aligning their interests with shareholders and incentivizing long-term value creation. The specific terms of the award, such as the vesting schedule and exercise price, are typical for director compensation packages.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash and equity.
• Stock options are a common component, similar to practices at companies like Biogen or Vertex Pharmaceuticals.
• Vesting schedules are typically time-based, encouraging long-term commitment, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the stock option award positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates